Gene therapy is such a simple and appealing idea. If you have the wrong version of a given gene, you just exchange it for the correct version, and you're cured. In practice, it has been anything but simple. Researchers had to make pacts with any number of devils, including retroviruses, in their attempts to smuggle the required genes into human cells. As yet, they simply don't have a gene vector that is both efficient and completely controllable.
Therefore, the history of gene therapy from the very first clinical trial in 1990 to this day has been a rollercoaster. One particularly discouraging low point was the death of 18-year-old Jesse Gelsinger in 1999, whose immune system overreacted to the invasion of the viral vector. There followed a much-needed high, when Alain Fischer at the Necker Hospital in Paris succeeded in curing the X-linked severe combined immune deficiency (X-SCID) of ten so-called bubble babies, using a retrovirus coaxed into delivering the missing gene into the children's bone marrow cells. This was the first ever example showing that gene therapy can actually cure a human disease.
By the beginning of this year, however, this study had suffered a severe setback when the second of the 10 children treated was diagnosed with leukemia. While the researchers had been aware that there was a small risk that the gene transfer might activate an oncogene, the observed frequency of cases suggests that the vector has a preference for inserting the gene in a place where it can cause cancer. Clearly, researchers need to return to the bench in order to find out why the inserted gene has a tendency to touch down in the wrong place.
News focus

Planning for gene therapy
In spite of some setbacks, gene therapy trials continue and the UK government is putting in place plans to bring the potential power of genetics into mainstream public heath care through its National Health Service. Michael Gross reports.
Britain's National Health Service (NHS) is famous for being cheaper than its continental European counterparts. The downside is that more and more treatments are either not available from the NHS, or only available after long waiting times. To patients who have experienced the long wait, the proposal to hitch up this slow colossus with the fast-moving research in genetics might appear a little bit puzzling.
On closer inspection, the White Paper [1] basically acknowledges that there has been revolutionary change in genetics, and that the public sector health care needs to do something to remain at least in touch with progress (if not exactly a world leader, as the paper grandiosely claims). It rounds up a variety of genetics-related issues, which have very different characteristics and political needs. Some can be addressed with legislation, others with money, others again with getting people to talk to each other.
The specific issues addressed in the report include: . (2002) 12,  R408) .
While the White Paper shows that the government is aware of the opportunities and risks brought about by new genetic methods and knowledge, many researchers will doubt whether its proclaimed goal of making the NHS 'a world leader in genetics' can be bought with such a small budget. Spread out over the population covered by the NHS, £50 million disperse into less than one pound per head. Contrast this with the expenditure on the war in Iraq, which has cost the British taxpayers several billion pounds so far, and you begin to realise that there may be something wrong with the number of zeroes in the genetics budget. For cystic fibrosis alone, a charity specialising on this disease has estimated the price tag for a breakthrough therapy at £6 million.
At the end of the day, the consumer using the NHS in a few years' time will probably be more likely than today to be offered genetic testing backed up with competent advice. But for gene therapy or pharmacogenetic assessment, they will probably have to wait a bit longer.
1. The White Paper on genetics is available from www.doh.gov.uk
NHS to swallow genetics pill
The mixed message of hope and danger emanating from this case is reflected in variable enthusiasm for gene therapy around the globe. In Germany, where the research ministry has cautiously supported such research since 1994, Ärzte Zeitung estimates that around 250 patients are currently undergoing experimental treatment involving gene transfer. All such trials must be approved by the 'Kommission Somatische Gentherapie', an expert committee formed by the scientific advisory board of the federal chamber of physicians (Bundesärztekammer). After the bad news from Paris broke, the committee halted all studies involving retroviruses for a careful reassessment of the risk situation. By now it seems certain that most of the studies will be continued. Only one, which was to target granulomatosis, is still blocked indefinitely.
In the United States, a new gene therapy trial targeting agedependent macula degeneration has been given the go-ahead in February. It will initially involve around 50 patients. In Britain, a smaller scale trial of X-SCID gene therapy, similar to the one at Paris, funded by the 'Jeans for Genes' campaign, has been carried out at Great Ormond Street Hospital in London. It reported its first cure in April 2002. At the beginning of this year, the study was suspended for a few months, but is now set to continue.
Meanwhile, the UK government has published an official report ('White Paper') on genetics, entitled 'Our inheritance -our future: Realising the potential of genetics in the NHS' with plans of incorporating recent advances in genetics into the mainstream healthcare offered by the National Health Service (NHS). The paper, prepared by the former Health Secretary Alan Milburn and presented by his successor John Reid, comprises the search for new treatments, including gene therapy, alongside with enhanced antenatal screening, geneticsrelated counselling, knowledge transfer measures, and legislation against DNA theft (see sidebar).
